Mannkind

Shares of MannKind Corp. (NASDAQ:MNKD) was the recipient of unusually large options trading activity on Monday. Traders acquired 11,596 put options on the company, Stock Ratings Network reports.This is an increase of approximately 114% compared to the average volume of 5,418 put options.

In other MannKind Corp. news, CFO Matthew J. Pfeffer sold 10,000 shares of MannKind Corp. stock in a transaction that occured on Thursday, August 1st. The stock was sold at an average price of $8.00, for a total transaction of $80,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

A number of research firms have recently commented on MNKD. Analysts at MLV Capital raised their price target on shares of MannKind Corp. from $6.00 to $8.00 in a research note to investors on Thursday, June 27th. They now have a “buy” rating on the stock. Separately, analysts at Piper Jaffray Cos. set a $8.40 price target on shares of MannKind Corp. in a research note to investors on Wednesday, June 26th. Finally, analysts at Brinson Patrick initiated coverage on shares of MannKind Corp. in a research note to investors on Friday, June 21st. They set an “outperform” rating on the stock.

Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $7.29.

Shares of MannKind Corp. (NASDAQ:MNKD) traded down 4.95% during mid-day trading on Monday, hitting $7.10. MannKind Corp. has a one year low of $1.82 and a one year high of $8.33. The stock’s 50-day moving average is currently $7.16. The company’s market cap is $2.017 billion.

MannKind Corp. (NASDAQ:MNKD) last released its earnings data on Friday, August 9th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.02. On average, analysts predict that MannKind Corp. will post $-0.47 earnings per share for the current fiscal year.

MannKind Corporation (NASDAQ:MNKD) is a development-stage biopharmaceutical company.

http://www.watchlistnews.com/2013/08/13/investors-purchase-high-volume-of-mannkind-corp-put-options-mnkd/